The FDA decision on ONS-5010 in May 2026 is the binary catalyst. Approval could drive significant upside; another CRL would likely be devastating given the $7.7M cash position and ongoing operating losses. The adjusted EPS miss and declining European sales add near-term pressure. Monitor the FDA decision closely — this is a high-risk, binary event stock.
Price Chart
Executive Summary
Outlook Therapeutics reported Q2 FY2026 results with GAAP net loss of $0.05/share (vs consensus $-0.12) and adjusted net loss of $0.16/share (vs consensus $-0.12). Revenue was $128K from initial LYTENAVA sales in Europe, but unit sales declined ~10% QoQ. The company completed a formal FDA dispute resolution meeting in April and expects a decision in May 2026, while cash stood at $7.7M (pre-April $4.2M offering).
Key Financial Metrics
Key Facts
- GAAP net loss per share: $(0.05) vs consensus $(0.12) — beat on GAAP basis due to $9.3M in non-cash gains (warrant liability + promissory note fair value changes)
- Adjusted (non-GAAP) net loss per share: $(0.16) vs consensus $(0.12) — miss of 33% on the Street metric
- Revenue: $128K from LYTENAVA European sales, down ~10% QoQ from Dec 2025 quarter
- Cash and equivalents: $7.7M as of March 31, 2026 (excluding $4.2M net from April 2026 registered direct offering)
- FDA formal dispute resolution meeting completed in April 2026; decision expected in May 2026
- Convertible promissory note restructured with maturity extended to December 2026
- March 2026 public offering raised ~$4.0M net; April 2026 registered direct offering raised $4.2M net
Financial Impact
Adjusted EPS miss of ~33% vs consensus; revenue of $128K with QoQ decline; cash runway extended by recent offerings but still limited
Risk Factors
- FDA decision expected May 2026 — negative outcome could render stock near-zero given limited cash
- Cash burn continues with only $7.7M (pre-April offering) — additional dilution likely
- European LYTENAVA unit sales declined ~10% QoQ despite early launch momentum
- High share count dilution: weighted average shares rose from 30.9M to 81.8M YoY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296119 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 424B5 | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | 8-K | $0.7564 $0.6379 | ▲ +15.67% | ▲ +13.67% | $0.5778 (+23.61%) |
Aug 14, 2026 7w ago | Press Release | $0.7564 $0.6379 | ▼ −15.67% | ▼ −13.67% | $0.5778 (−23.61%) |
Aug 13, 2026 7w ago | Press Release | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Aug 12, 2026 7w ago | 8-K | $0.8888 $0.6600 | ▲ +25.74% | ▲ +24.00% | $0.5778 (+34.99%) |
Jul 24, 2026 9w ago | 8-K | $1.07 $0.6090 | ▼ −42.82% | ▼ −46.12% | $0.5778 (−45.75%) |
Jul 24, 2026 10w ago | Press Release | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 23, 2026 10w ago | 8-K | $1.41 $0.6472 | ▼ −53.94% | ▼ −57.56% | $0.5778 (−58.88%) |
Jul 22, 2026 10w ago | EFFECT | $1.34 $0.6901 | ▼ −48.50% | ▼ −51.40% | $0.5778 (−56.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access